These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 31631965)

  • 1. Update On Cenegermin Eye Drops In The Treatment Of Neurotrophic Keratitis.
    Sheha H; Tighe S; Hashem O; Hayashida Y
    Clin Ophthalmol; 2019; 13():1973-1980. PubMed ID: 31631965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cenegermin for the treatment of neurotrophic keratitis.
    Sacchetti M; Bruscolini A; Lambiase A
    Drugs Today (Barc); 2017 Nov; 53(11):585-595. PubMed ID: 29451275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cenegermin: A Review in Neurotrophic Keratitis.
    Deeks ED; Lamb YN
    Drugs; 2020 Apr; 80(5):489-494. PubMed ID: 32185680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of rh-NGF in the management of neurotrophic keratopathy.
    Roszkowska AM; Spinella R; Calderone A; Sindoni M; Wowra BH; Kozak M; Sajak-Hydzik K; Aliò J
    Front Ophthalmol (Lausanne); 2024; 4():1408587. PubMed ID: 39040985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical Recombinant Human Nerve Growth Factor (Cenegermin) for Neurotrophic Keratopathy: A Multicenter Randomized Vehicle-Controlled Pivotal Trial.
    Pflugfelder SC; Massaro-Giordano M; Perez VL; Hamrah P; Deng SX; Espandar L; Foster CS; Affeldt J; Seedor JA; Afshari NA; Chao W; Allegretti M; Mantelli F; Dana R
    Ophthalmology; 2020 Jan; 127(1):14-26. PubMed ID: 31585826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Treatment for Neurotrophic Corneal Ulcer Using Topical Cenegermin (OXERVATE™) Containing Recombinant Human Nerve Growth Factor.
    Ahuja AS; Bowden FW; Robben JL
    Cureus; 2020 Nov; 12(11):e11724. PubMed ID: 33391953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent innovations with drugs in clinical trials for neurotrophic keratitis and refractory corneal ulcers.
    Bremond-Gignac D; Daruich A; Robert MP; Chiambaretta F
    Expert Opin Investig Drugs; 2019 Nov; 28(11):1013-1020. PubMed ID: 31596151
    [No Abstract]   [Full Text] [Related]  

  • 8. Topical human recombinant nerve growth factor for stage 1 Neurotrophic Keratitis: Retrospective case series of cenegermin treatment.
    Epitropoulos AT; Weiss JL
    Am J Ophthalmol Case Rep; 2022 Sep; 27():101649. PubMed ID: 35938145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topical cenegermin 0.002% for pediatric neurotrophic keratopathy.
    Elhusseiny AM; Traish AS; Saeed HN; Mantagos IS
    Eur J Ophthalmol; 2022 Nov; 32(6):3420-3424. PubMed ID: 35469461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resolution of a neurotrophic keratopathy associated hypopyon with cenegermin.
    Zambino N; Syed ZA
    Am J Ophthalmol Case Rep; 2021 Sep; 23():101113. PubMed ID: 34307960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurotrophic keratopathy: Clinical presentation and effects of cenegermin.
    Bu JB; Gericke A; Pfeiffer N; Wasielica-Poslednik J
    Am J Ophthalmol Case Rep; 2022 Jun; 26():101488. PubMed ID: 35330588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term clinical efficacy of topical treatment with recombinant human nerve growth factor in neurotrophic keratopathy: a novel cure for a rare degenerative corneal disease?
    Bruscolini A; Marenco M; Albanese GM; Lambiase A; Sacchetti M
    Orphanet J Rare Dis; 2022 Feb; 17(1):57. PubMed ID: 35172847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case report of pediatric neurotrophic keratopathy in pontine tegmental cap dysplasia treated with cenegermin eye drops.
    Fausto R; Ceccuzzi R; Micheletti E; Clerici R; Riva I; Katsanos A; Oddone F; Quaranta L
    Medicine (Baltimore); 2020 Jul; 99(30):e20816. PubMed ID: 32791670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Topical Cenegermin in Management of a Cornea Transplant in a Functionally Monocular Patient with Neurotrophic Keratitis and Facial Nerve Palsy: A Case Report.
    Pocobelli A; Komaiha C; De Carlo L; Pocobelli G; Boni N; Colabelli Gisoldi RAM
    Int Med Case Rep J; 2020; 13():617-621. PubMed ID: 33204181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and instrumental assessment of the corneal healing in moderate and severe neurotrophic keratopathy treated with rh-NGF (Cenegermin).
    Roszkowska AM; Inferrera L; Aragona E; Gargano R; Postorino EI; Aragona P
    Eur J Ophthalmol; 2022 Nov; 32(6):3402-3410. PubMed ID: 35473440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase IV Multicenter, Prospective, Open-Label Clinical Trial of Cenegermin (rhNGF) for Stage 1 Neurotrophic Keratopathy (DEFENDO).
    Hamrah P; Massaro-Giordano M; Schanzlin D; Holland E; Berdy G; Goisis G; Pasedis G; Mantelli F
    Ophthalmol Ther; 2024 Feb; 13(2):553-570. PubMed ID: 38175466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II Randomized, Double-Masked, Vehicle-Controlled Trial of Recombinant Human Nerve Growth Factor for Neurotrophic Keratitis.
    Bonini S; Lambiase A; Rama P; Sinigaglia F; Allegretti M; Chao W; Mantelli F;
    Ophthalmology; 2018 Sep; 125(9):1332-1343. PubMed ID: 29653858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in the Medical Management of Neurotrophic Keratitis.
    Dohlman TH; Singh RB; Dana R
    Semin Ophthalmol; 2021 May; 36(4):335-340. PubMed ID: 33705259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epithelial Plaque Formation Secondary to Recombinant Human Nerve Growth Factor.
    Weinlander E; Ling J; Reddy A; Nallasamy N
    Cornea; 2020 Sep; 39(9):1174-1176. PubMed ID: 32141943
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.